Scholarlink

<p>Window-of-opportunity trials are a path to screen effective agents and optimize dose in breast cancer risk reduction. We review the scientific evidence regarding the utility of window-of-opportunity trials to screen effective agents and optimize dose for successful risk reduction/interception of breast cancer. Low-dose tamoxifen was evaluated in a window-of-opportunity trial and then validated in a phase-III trial. We are now studying similar activity with low-dose exemestane.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Window-of-opportunity trials to screen effective agents and optimize dose in breast cancer prevention

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月9日

查看全文
  • G. Aurilio,
  • D. Serrano,
  • M. Lazzeroni,
  • A. Guerrieri-Gonzaga,
  • H. Johansson,
  • S. Gandini,
  • I. M. Briata,
  • M. D’Amico,
  • S. Spinaci,
  • P. Veronesi,
  • V. Galimberti,
  • M. Intra,
  • B. M. Heckman-Stoddard,
  • E. Szabo,
  • G. Viale,
  • B. Bonanni,
  • A. DeCensi

摘要

Window-of-opportunity trials are a path to screen effective agents and optimize dose in breast cancer risk reduction. We review the scientific evidence regarding the utility of window-of-opportunity trials to screen effective agents and optimize dose for successful risk reduction/interception of breast cancer. Low-dose tamoxifen was evaluated in a window-of-opportunity trial and then validated in a phase-III trial. We are now studying similar activity with low-dose exemestane.